Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
11.7
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年1月1日〜2025年3月31日ConsolidatedIFRSNet Sales826,981¥ millionYear on year +11.7%Progress 25.3%
Operating profit248,758¥ millionYear on year +15.3%Progress 37.1%
Ordinary income226,069¥ millionYear on year +12.3%
Net income attributable to owners of the parent157,480¥ millionYear on year +0.1%Progress 35.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share88.69円
Financial position at period-end
Total assets7,943,210¥ million
of which net assets 3,865,395 ¥ millionEquity ratio 47.6%vs. prior year-end +2.6pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-6,572
Investment-81,091
Financials-180,119
Net change-267,782
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥809,364 million
Segment revenueTobacco ¥764,807 million (YoY +12.3%), Pharmaceuticals ¥25,388 million (YoY +8.8%), Processed Foods ¥36,468 million (YoY +2.2%)
Segment profitTobacco ¥273,248 million (YoY +17.8%), Pharmaceuticals ¥4,493 million (YoY +17.0%), Processed Foods ¥794 million (YoY -60.7%)
Regional sales¥200,993 million (YoY +0.7%), ¥176,666 million (YoY +2.4%), ¥360,875 million (YoY +28.3%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥3,273,000 million (YoY +3.9%)
Operating profit¥671,000 million (YoY +107.4%)
Ordinary incomeNot disclosed
Net income¥450,000 million (YoY +151.1%)
Annual Dividend Forecast¥194 → ¥194（0.0%）
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name None
Material subsequent events普通社債を発行したほか、2025年5月7日付で、医薬事業を塩野義製薬へ譲渡する会社分割契約と、鳥居薬品株式を譲渡する合意書を締結しました。医薬事業の譲渡価格は予定額5,397百万円、鳥居薬品株式の譲渡価格は予定額70,342百万円です。
Impairment lossAmount ¥764 million / Subject assets Not disclosed
Depreciation and amortization¥48,858 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for analysts and institutional investors)
Issued Shares at Period-End2,000,000,000
Treasury Shares at Period-End224,535,707
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年1月1日〜2025年3月31日 |
| Net Sales | ¥826,981 million (YoY +11.7%) |
| Operating profit | ¥248,758 million (YoY +15.3%) |
| Ordinary income | ¥226,069 million (YoY +12.3%) |
| Profit attributable to owners of the parent | ¥157,480 million (YoY +0.1%) |
| Net income per share | 88.69円 |
| Equity ratio | End of the current fiscal period 47.6% / End of previous period 45.0% |
| Total assets | ¥7,943,210 million |
| Net assets | ¥3,865,395 million |
| Cash flows from operating activities | ¥-6,572 million |
| Cash flows from investing activities | ¥-81,091 million |
| Cash flows from financing activities | ¥-180,119 million |
| Cash and cash equivalents at end of period | ¥809,364 million |
| Full-year earnings forecast | Net Sales ¥3,273,000 million (YoY +3.9%) / Operating profit ¥671,000 million (YoY +107.4%) / Ordinary income Not disclosed / Net income ¥450,000 million (YoY +151.1%) |
| Annual Dividend Forecast | ¥194 → ¥194（0.0%） |
| Segment revenue | Tobacco ¥764,807 million (YoY +12.3%), Pharmaceuticals ¥25,388 million (YoY +8.8%), Processed Foods ¥36,468 million (YoY +2.2%) |
| Segment profit | Tobacco ¥273,248 million (YoY +17.8%), Pharmaceuticals ¥4,493 million (YoY +17.0%), Processed Foods ¥794 million (YoY -60.7%) |
| Regional sales | ¥200,993 million (YoY +0.7%), ¥176,666 million (YoY +2.4%), ¥360,875 million (YoY +28.3%) |
| Depreciation and amortization | ¥48,858 million |
| Impairment loss | Amount ¥764 million / Subject assets Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | 普通社債を発行したほか、2025年5月7日付で、医薬事業を塩野義製薬へ譲渡する会社分割契約と、鳥居薬品株式を譲渡する合意書を締結しました。医薬事業の譲渡価格は予定額5,397百万円、鳥居薬品株式の譲渡価格は予定額70,342百万円です。 |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 2,000,000,000 |
| Treasury Shares at Period-End | 224,535,707 |
Items this document does not state (7)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogBreakdown of extraordinary income (loss)Factors Behind Changes in Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.四半期業績の増減要因は短信本文では説明されず、決算説明会資料を参照するとされています。医薬事業等の譲渡については、創薬力を発展させ、塩野義製薬の下で事業展開することが最善と判断したとしています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.